Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961630 · ClinicalTrials.gov registry record · Early Phase 1
Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction
A Early Phase 1 study of Myocardial Injury After Noncardiac Surgery, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06961630 is a Early Phase 1 study of Myocardial Injury After Noncardiac Surgery that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06961630, a Early Phase 1 study of Myocardial Injury After Noncardiac Surgery, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study drug adherence, and optimize study design (entry criteria, study endpoints, sample size calculation, site selection) and recruitment strategies for the future multicenter randomized clinical trial studying biomarker-based care in post-operative patients at elevated cardiovascular (CV) risk.
Conditions Studied
Interventions
- DRUG Atorvastatin
- DRUG Rivaroxaban
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2027-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961630
The ClinicalTrials.gov registry entry for NCT06961630 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myocardial Injury After Noncardiac Surgery appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin is the first listed.
NCT06961630 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06961630 about?
NCT06961630 is a clinical study titled "Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction". The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study ...
What is the current status of trial NCT06961630?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2025-10-07. Estimated completion is 2027-03-31.
What conditions does trial NCT06961630 study?
This clinical trial studies the following conditions: Myocardial Injury After Noncardiac Surgery.
What interventions are being tested in trial NCT06961630?
The interventions under investigation include: Atorvastatin (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT06961630?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961630 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.